Clinical Trial Update: Subconjunctival Bevacizumab and Recurrent Pterygium [Phase 2, Phase 3]

View source ↗

Summary

This document reports an update on a Phase 2/3 clinical trial evaluating subconjunctival bevacizumab for recurrent pterygium, with the study status indicated as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Instituto de Olhos de Goiania | Conditions: Recurrent Pterygium | Phase 2, Phase 3 | Status: COMPLETED